clinical trial · NCT03432520
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
Spark Therapeutics, Inc.·—·active not recruiting·n = 29
Hemophilia ASPK-8011SPK-8016
brief summary
This long-term follow-up study will continue to evaluate the long-term safety and efficacy of SPK-8011 and SPK-8016 in males with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any Spark-sponsored SPK-8011 or SPK-8016 study.
started
Aug 14, 2018
primary completion
Dec 1, 2032
completion
Dec 1, 2032
last updated
Nov 29, 2024
detailed description
This study will follow patients with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any prior Spark-sponsored SPK-8011 or SPK-8016 study. Participants will be followed for up to a total of 10 years post infusion (including the time on the dosing study).
official title
A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol